ATE384800T1 - Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten - Google Patents

Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten

Info

Publication number
ATE384800T1
ATE384800T1 AT01988344T AT01988344T ATE384800T1 AT E384800 T1 ATE384800 T1 AT E384800T1 AT 01988344 T AT01988344 T AT 01988344T AT 01988344 T AT01988344 T AT 01988344T AT E384800 T1 ATE384800 T1 AT E384800T1
Authority
AT
Austria
Prior art keywords
fusion proteins
treatment
protease
protease inhibitors
diseases
Prior art date
Application number
AT01988344T
Other languages
English (en)
Inventor
Philip Barr
Helen Gibson
Philip Pemberton
Original Assignee
Arriva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arriva Pharmaceuticals Inc filed Critical Arriva Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE384800T1 publication Critical patent/ATE384800T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • C07K14/8125Alpha-1-antitrypsin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01988344T 2000-12-18 2001-12-18 Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten ATE384800T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25669900P 2000-12-18 2000-12-18
US33196601P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ATE384800T1 true ATE384800T1 (de) 2008-02-15

Family

ID=26945535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988344T ATE384800T1 (de) 2000-12-18 2001-12-18 Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten

Country Status (7)

Country Link
EP (1) EP1366175B1 (de)
JP (2) JP4426179B2 (de)
AT (1) ATE384800T1 (de)
AU (2) AU4166102A (de)
CA (1) CA2430973A1 (de)
DE (1) DE60132632T2 (de)
WO (1) WO2002050287A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510657A (ja) * 2002-12-06 2006-03-30 アライバ ファーマシューティカルズ,インコーポレイティド 中耳炎の処置のための方法および組成物
JP2007534611A (ja) * 2003-04-08 2007-11-29 ジェノバ・リミテッド 心臓血管障害に関連する分泌ポリペプチド種
EP2287326A1 (de) 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Verfahren zur Protein-Produktion in Hefe
SE0302559D0 (sv) 2003-09-25 2003-09-25 Astrazeneca Ab Method
EP1737499A4 (de) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc Behandlung von chronisch obstruktiver lungenerkrankung durch inhalation von niedrigen dosen eines proteasehemmers
JP2007037434A (ja) * 2005-08-02 2007-02-15 Yamaguchi Univ 膵β細胞特異的に発現される人工タンパク質、該タンパク質をコードしたレポーター遺伝子及び膵β細胞量の計測方法
CA2647246C (en) * 2006-03-30 2015-06-23 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
WO2010041617A1 (ja) * 2008-10-09 2010-04-15 公立大学法人横浜市立大学 β-アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ-2インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質
MX2013002556A (es) * 2010-09-14 2013-05-28 Hoffmann La Roche Polipeptido de fusion de dedo de serpina.
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR102231139B1 (ko) * 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR20140108516A (ko) 2011-12-30 2014-09-11 그리폴스, 에스.에이. 폐 악화의 발현 또는 진행을 지연시키기 위한 알파1-프로테이나제 억제제
JP6436401B2 (ja) * 2013-04-30 2018-12-12 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 弾性繊維損傷マーカーの解析
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
CN105764523A (zh) * 2013-09-18 2016-07-13 詹姆斯库克大学 抗炎蛋白及使用方法
IT202000012370A1 (it) * 2020-05-26 2021-11-26 Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L Composizione comprendente pepstatina e acido alginico o un suo sale e suo uso
AU2021375735A1 (en) * 2020-11-06 2023-06-08 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
DE3709255A1 (de) * 1987-03-20 1988-09-29 Hoechst Ag Hybridserpine und dafuer kodierende dna
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
JP2001525669A (ja) * 1997-05-12 2001-12-11 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 細胞遊走の阻害のための方法および構築物
AU1101501A (en) * 1999-10-27 2001-05-08 K-Quay Enterprises, Llc Methods and compositions for treatment of keratoconus using protease inhibitors

Also Published As

Publication number Publication date
JP4426179B2 (ja) 2010-03-03
EP1366175A2 (de) 2003-12-03
WO2002050287A3 (en) 2003-09-18
JP2004537970A (ja) 2004-12-24
DE60132632D1 (de) 2008-03-13
WO2002050287A2 (en) 2002-06-27
EP1366175B1 (de) 2008-01-23
AU4166102A (en) 2002-07-01
JP2009297031A (ja) 2009-12-24
DE60132632T2 (de) 2009-01-22
CA2430973A1 (en) 2002-06-27
AU2002241661B2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
DE60132632D1 (de) Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten
Amour et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs
NO923469L (no) Chymotrypsin-lignende proteaser og deres inhibitorer
HUP9902698A2 (hu) Humán bikunin
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
DE60218179D1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
ATE108205T1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO1996035788A3 (en) Kunitz type protease inhibitors
DE602005023133D1 (de) Prozess und reagenzien für extraktion von rns von fraktionierten blutleukozyten
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
DE69935078D1 (de) Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
WO2002010357A3 (en) Gsk3 polypeptides
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
Konttinen et al. Substrate specificity and activation mechanisms of collagenase from human rheumatoid synovium
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
EP1497326A4 (de) Prothrombin aktivierendes protein
ATE251904T1 (de) Verwendung von bronopol zur behandlung von krankheiten beim fisch
ATE452984T1 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
DE60123109D1 (de) Mit schizophrenie in zusammenhang stehendes gen, das für ein potential-abhängiges ionkanal kodiert

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties